Screener
R&D at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost.
The source filing: Viridian Therapeutics, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:31 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001590750-26-000018
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue - related parties | 51 | 75 | 186 | 147 |
| Total revenues | 284 | 75 | 425 | 147 |
| Operating expenses: | ||||
| Research and development (1) | 71,577 | 86,626 | 149,208 | 163,461 |
| Selling, general and administrative | 54,975 | 20,216 | 93,654 | 37,319 |
| Total operating expenses | 126,552 | 106,842 | 242,862 | 200,780 |
| Loss from operations | (126,268) | (106,767) | (242,437) | (200,633) |
| Other income (expense), net: |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Viridian Therapeutics, Inc.'s R&D?
- Viridian Therapeutics, Inc. (VRDN) reported R&D of $71.58M in Q2 2026.
- How has Viridian Therapeutics, Inc.'s R&D changed year-over-year?
- Viridian Therapeutics, Inc.'s R&D decreased by 17.4% year-over-year, from $86.63M to $71.58M.
- What is the long-term trend for Viridian Therapeutics, Inc.'s R&D?
- Over 4 years (2021 to 2025), Viridian Therapeutics, Inc.'s R&D has grown at a 56.2% compound annual growth rate (CAGR), from $56.89M to $338.93M.
- What does R&D mean?
- Costs of research activities to discover new knowledge and development activities to translate research into new or improved products, services, processes, or technologies.
Ask your AI about Viridian Therapeutics, Inc.'s r&d.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude